Prof Jong-Mu Sun, medical oncologist at Samsung Medical Center, Seoul, Republic of Korea presented the safety run-in results from the phase 3 LEAP-014 study, evaluating first-line lenvatinib plus pembrolizumab and chemotherapy for patients with metastatic esophageal squamous cell carcinoma.
With the educational support of:
 |
 |